Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by left
ventricular hypertrophy, hyperdynamic contraction, and impaired relaxation of the heart …

Force generation in striated muscle is primarily controlled by structural changes in the actin-
containing thin filaments triggered by an increase in intracellular calcium concentration …

Small angle X-ray fiber diffraction is the method of choice for obtaining molecular level
structural information from striated muscle fibers under hydrated physiological conditions …

Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general
population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and …

Proline substitutions within the coiled-coil rod region of the β-myosin gene (MYH7) are the
predominant mutations causing Laing distal myopathy (MPD1), an autosomal dominant …

Mavacamten is a FDA-approved small-molecule therapeutic designed to regulate cardiac
function at the sarcomere level by selectively but reversibly inhibiting the enzymatic activity …

BACKGROUND: Modulating myosin function is a novel therapeutic approach in patients with
cardiomyopathy. Danicamtiv is a novel myosin activator with promising preclinical data that …

Contraction of the heart is driven by cyclical interactions between myosin and actin filaments
powered by ATP hydrolysis. The modular structure of heart muscle and the organ-level …

The biochemical SRX (super-relaxed) state of myosin has been defined as a low ATPase
activity state. This state can conserve energy when the myosin is not recruited for muscle …

Contraction in striated muscle is classically described as regulated by calcium-mediated
structural changes in the actin-containing thin filaments, which release the binding sites for …